Seladelpar

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 93 publications

Sustained and Clinically Meaningful Improvements in Moderate to Severe Pruritus Patients With PBC Treated With Seladelpar: Results From the ASSURE Study Up to 30 Months.

Sustained and Clinically Meaningful Improvements in Moderate to Severe Pruritus Patients With PBC Treated With Seladelpar: Results From the ASSURE Study Up to 30 Months.

Journal: Gastroenterology & hepatology

Published: February 09, 2026

Seladelpar Is Associated With a Sustained Reduction in Cholestatic Markers and a Consistent Safety Profile in Patients With PBC Treated Up to 48 Months in the Ongoing, Open-Label ASSURE Study.

Seladelpar Is Associated With a Sustained Reduction in Cholestatic Markers and a Consistent Safety Profile in Patients With PBC Treated Up to 48 Months in the Ongoing, Open-Label ASSURE Study.

Journal: Gastroenterology & hepatology

Published: February 09, 2026

36 Months of Treatment With Seladelpar Is Associated With Stable or Improved Liver Stiffness in Patients With PBC.

36 Months of Treatment With Seladelpar Is Associated With Stable or Improved Liver Stiffness in Patients With PBC.

Journal: Gastroenterology & hepatology

Published: February 09, 2026

Consensus statements of the Hellenic Autoimmune Liver Diseases Study Group on the diagnosis and current management of primary biliary cholangitis.

Consensus statements of the Hellenic Autoimmune Liver Diseases Study Group on the diagnosis and current management of primary biliary cholangitis.

Journal: Annals of gastroenterology

Published: December 24, 2025

Mechanistic Rationale of Seladelpar's Clinical Efficacy through the Selective PPAR-δ Activation in Primary Biliary Cholangitis.

Mechanistic Rationale of Seladelpar's Clinical Efficacy through the Selective PPAR-δ Activation in Primary Biliary Cholangitis.

Journal: Pharmacological research

Published: December 18, 2025

Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.

Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.

Journal: Alimentary pharmacology & therapeutics

Published: December 10, 2025

Peroxisome Proliferator-Activated Receptor α/δ/γ Activation Profile by Endogenous Long-Chain Fatty Acids.

Peroxisome Proliferator-Activated Receptor α/δ/γ Activation Profile by Endogenous Long-Chain Fatty Acids.

Journal: International journal of molecular sciences

Published: November 12, 2025

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Journal: Hepatology communications

Published: October 24, 2025

Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial.

Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial.

Journal: Alimentary pharmacology & therapeutics

Published: October 23, 2025

Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis.

Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis.

Journal: Alimentary pharmacology & therapeutics

Published: October 21, 2025

Recent Advances in Primary Biliary Cholangitis Treatment.

Recent Advances in Primary Biliary Cholangitis Treatment.

Journal: Clinics in liver disease

Published: October 18, 2025

An update on novel investigational agents for the treatment of primary biliary cholangitis.

An update on novel investigational agents for the treatment of primary biliary cholangitis.

Journal: Expert opinion on investigational drugs

Published: October 13, 2025

Showing 1-12 of 93

Last Updated: 04/28/2026